Company Overview and News

Open Square Fund Q1 2018 Commentary (Part 2 Of 2)

5h seekingalpha
The market is currently distracted by the narratives of technology to the exclusion of other sectors.
Upvote Downvote

Weekly Oil Markets Recap - Energy Stocks Aren't So Hated Anymore

2018-04-15 seekingalpha
Energy stocks have managed to outperform the broader markets by 9.8% since the middle of March, the steepest and fastest outperformance since the oil downturn.
Upvote Downvote

Buy Canadian Heavy Oil Producers As The WCS-WTI Discount Narrows

2018-04-03 seekingalpha
Canadian heavy oil producer equities have diverged greatly from the recent improvement in Western Canadian Select prices or WCS. The discount between WCS and WTI continues to narrow allowing knowledgeable investors to take advantage of the complacency in Canada.
Upvote Downvote

This Small-Cap Oil Producer Is Too Cheap To Ignore

2018-03-28 seekingalpha
Concerns over Canadian heavy oil are overblown as WCS spreads have already started to tighten and crude by rail shipments increasing.
Upvote Downvote

BRIEF-Gear Energy Announces Operational Update And 2018 Revised Outlook

2018-03-21 reuters
* GEAR ENERGY LTD - SEES 2018 CAPITAL AND ABANDONMENT EXPENDITURES OF $50 MILLION Source text for Eikon: Further company coverage:
Upvote Downvote

Canada Is The Worst Performing Equity Market Over The Last 10-Years, But With Inflation Coming, What Does That Mean?

2018-02-26 seekingalpha
Note: This was one of the write-ups in our HFI Research weekly flagship report, What Changed This Week 2-10-18. If you are interested in more of these write-ups, please see here for more info. This article was first published on February 10, 2018.
Upvote Downvote

An In-Depth Look At Eagle Energy's Operations, Production Outlook, And Profitability

2018-02-13 seekingalpha
Following an in-depth look at the asset portfolio in a previous piece, I review the operations, production outlook, and profitability of Eagle Energy.
Upvote Downvote

Weekly Oil Markets Recap - The Pullback

2018-02-05 seekingalpha
Oil prices have diverged from the underlying fundamental factors as the recent price moves have closely correlated with macro factors like the USD and euro.
Upvote Downvote

Marketplace Authors' Top Picks For 2018

2018-01-06 seekingalpha
We wrap up our Year End Marketplace Roundtable series with the good stuff - authors' sharing some of their best ideas for 2018.
Upvote Downvote

HFI Research - Best Ideas Going Into 2018

2018-01-03 seekingalpha
CRC trades at 3x FCF at $60/bbl Brent with the potential to trade to just 1x FCF at $70/bbl! The market remains overly pessimistic on oil prices.
Upvote Downvote

Energy: At The Markets' Whim

2017-12-29 seekingalpha
Seven of our Marketplace authors weigh in on the sector - especially oil and natural gas - where we've been and where we're headed in 2018.
Upvote Downvote

Granite Oil: Solid As A Rock Or Out Of Gas

2017-12-27 seekingalpha
Granite Oil inherited the Ferguson Alberta Bakken trend from predecessor DeeThree, with the goal of being a stable cashflow-generating dividend distributor.
Upvote Downvote

What's Going On With Western Canadian Select And What It Means For Gear Energy

2017-12-21 seekingalpha
There has been a lot of media coverage on why Canadian heavy oil (Western Canadian Select) is selling at a big discount.
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...